February 14, 2024

Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS

Year

2024

Assets in this page

Download assets

  • pdf file

    Current Report ESPI 10/2024

    Download